Rhenman & Partners Asset Management Boosts BioMarin Pharmaceutical Holdings

The asset management firm increased its stake in the biotech company by 24.7% in the third quarter.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Rhenman & Partners Asset Management AB grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 24.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund now owns 186,650 shares of the biotechnology company's stock, worth approximately $10.11 million.

Why it matters

BioMarin Pharmaceutical is a leading biotech company focused on developing therapies for rare genetic and metabolic diseases. The increase in Rhenman & Partners' stake suggests the firm sees long-term potential in the company's pipeline and commercial products.

The details

Rhenman & Partners Asset Management added 37,000 shares of BioMarin to its portfolio in the third quarter, bringing its total holdings to 186,650 shares. This represents about 0.10% of BioMarin's outstanding shares. The asset management firm cited BioMarin's strong product portfolio and promising drug candidates in its decision to increase its stake in the company.

  • Rhenman & Partners disclosed its increased BioMarin holdings in a Q3 2026 SEC filing.

The players

Rhenman & Partners Asset Management AB

A Swedish asset management firm that focuses on investments in the healthcare and life sciences sectors.

BioMarin Pharmaceutical Inc.

A biopharmaceutical company that develops and commercializes therapies for rare genetic and metabolic diseases.

Got photos? Submit your photos here. ›

The takeaway

Rhenman & Partners' increased stake in BioMarin Pharmaceutical signals the asset manager's confidence in the biotech company's ability to continue growing its rare disease drug portfolio and delivering value for shareholders.